Effects of the endocannabinoid transport inhibitors AM404 and UCM707 on diabetic neuropathy in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 11, 2009, Pages 1127-1131

  Hasanein, Parisa ^a   Soltani, Nepton ^b  

^a BU ALI SINA UNIVERSITY   (Iran)

^b HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AM404; Diabetes; Hyperalgesia; Rat; UCM707

Indexed keywords

ENDOCANNABINOID; FORMALDEHYDE; GLUCOSE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; STREPTOZOCIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; GLUCOSE BLOOD LEVEL; HYPERALGESIA; HYPERGLYCEMIA; MALE; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; RAT; STREPTOZOCIN DIABETES; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; FURANS; HYPERALGESIA; HYPERGLYCEMIA; MALE; PAIN; PAIN MEASUREMENT; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; POLYUNSATURATED ALKAMIDES; RATS;

EID: 70449500253     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05197.x     Document Type: Article

References (29)

1. Obrosova IG. Update on the pathogenesis of diabetic neuropathy. Curr. Diab. Rep. 2003 3 : 439 445.
2. Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur. J. Int. Med. 2001 12 : 20 7.
3. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993 36 : 150 154.
4. Freshwater JD, Malmberg AB, Calcutt NA. Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 2002 51 : 2249 2255.
5. Fox A, Eastwood C, Gentry C, Manning D, Urban L. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 1999 81 : 307 316.
6. Courteix C, Bourget P, Caussade F et al. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J. Pharmacol. Exp. Ther. 1998 285 : 63 70.
7. Malmberg AB, Yaksh TL, Calcutt NA. Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic rats. Neurosci. Lett. 1993 161 : 45 8.
8. Di Marzo V, Fontana A, Cadas H et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994 372 : 686 691.
9. Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006 8 : E693 708.
10. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 2001 298 : 7 14.
11. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 2002 449 : 99 103.
12. Pertwee RG. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Invest. Drugs 2000 9 : 1553 1571.
13. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. 2001 44 : 4505 4508.
14. La Rana G, Russo R, Campolongo P et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J. Pharmacol. Exp. Ther. 2006 317 : 1365 1371.
15. Mitchell VA, Greenwood R, Jayamanne A, Vaughan CW. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin. Exp. Pharmacol. Physiol. 2007 34 : 1186 1190.
16. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: Novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 2007 152 : 624 632.
17. Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res. 2003 987 : 176 185.
18. Abbott FV, Franklin KB, Westbrook RF. The formalin test: Scoring properties of the first and second phases of the pain response in rats. Pain 1995 60 : 91 102.
19. Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R. The formalin test: A validation of the weighted-scores method of behavioural pain rating. Pain 1993 54 : 43 50.
20. Manning BH, Franklin KB. Morphine analgesia in the formalin test: Reversal by microinjection of quaternary naloxone into the posterior hypothalamic area or periaqueductal gray. Behav. Brain. Res. 1998 92 : 97 102.
21. 1 receptors in models of diabetic neuropathy. J. Pharmacol. Exp. Ther. 2007 323 : 508 515.
22. 1 receptor density in the hippocampus of streptozotocin-induced diabetic rats. Exp. Neurol. 2007 204 : 479 484.
23. Costa B, Siniscalco D, Trovato AE et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. 2006 148 : 1022 1032.
24. Rodella LF, Borsani E, Rezzani R, Ricci F, Buffoli B, Bianchi R. AM404, an inhibitor of anandamide reuptake decreases Fos immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. Eur. J. Pharmacol. 2005 508 : 139 146.
25. Ceseña RM, Calcutt NA. Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. Neurosci. Lett. 1999 262 : 101 104.
26. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ. Intrathecal GM1 ganglioside and local nerve anesthesia reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res. 1992 584 : 28 53.
27. Fegley D, Gaetani S, Duranti A et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexylcarbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 2005 313 : 352 358.
28. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fernandez-Ruiz JJ, Ramos JA. Endocannabinoid transporter inhibitors. Curr. Med. Chem. Cent. Nerv. Syst. Agents 2002 2 : 129 141.
29. Agarwal N, Pacher P. Tegeder I et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007 10 : 870 879.